Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2024 01:00 ET | Source: Ultimovacs ASA

Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma

The Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) was granted based on results from the randomized Phase II clinical trial NIPU, which showed improved overall survival...
February 14, 2024 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

STAFFORD, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an...
February 14, 2024 01:00 ET | Source: Ultimovacs ASA

Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update

Readout of topline result expected in March 2024 from UV1 randomized Phase II trial INITIUM in Ultimovacs’ lead indication, advanced malignant melanomaTopline result will report primary endpoint of...
February 12, 2024 08:00 ET | Source: Medigene AG

Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors

Gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma selected as initial clinical indications for lead program MDG1015MDG1015 is a first-in-class, third generation TCR-T...
February 05, 2024 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Provide Corporate Progress Updates at Several Events in February-March

Keystone Symposia Epigenetic Mechanisms and Cancer TreatmentBio-Neuroscience17th Annual European Life Sciences CEO Forum BIO-Europe Spring 2024 MADRID, Spain and BOSTON, Feb. 05, 2024 (GLOBE...
February 05, 2024 01:00 ET | Source: Ultimovacs ASA

Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma

Fast Track designation is granted for UV1 in combination with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma to improve overall...
February 02, 2024 06:30 ET | Source: Regeneron Pharmaceuticals, Inc.

Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM(a)(b), revenues increased 14%Full year 2023 revenues increased 8% to $13.12 billion versus...
February 01, 2024 07:30 ET | Source: Purple Biotech Ltd.

Purple Biotech Reaches Recommended Phase 2 Dose for NT219

REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
January 30, 2024 08:00 ET | Source: Immutep Limited

Immutep Quarterly Activities Report Q2 FY24

Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients expressing...
January 30, 2024 05:12 ET | Source: Research and Markets

Bispecific CD3 Molecules in Oncology, 2024 Analytical Handbook - Get Early Insights into Technologies, Startups, Emerging Clinical Trial Results, Drug Approvals, and the Ever-Changing Competitive Landscape

Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Bispecific CD3 Molecules in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.There is a considerable and robust...